Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd R Burmester

Showing results (151-160 of 335) with videos related to

Pageof 34
Sort By:
RMD Open|May 28, 2021
Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposureGerd R Burmester, Peter Nash, Bruce E Sands, et al.
Rheumatology and Therapy|April 29, 2024
Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical TrialsGerd R Burmester, Jayne Stigler, Andrea Rubbert-Roth, et al.
Advances in Therapy|January 3, 2024
Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled TrialsEduardo Mysler, Gerd R Burmester, Christopher D Saffore, et al.
EULAR Rheumatology Open|June 29, 2026
Efficacy, safety, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab intravenously administered to adults with active rheumatoid arthritis and an inadequate response to methotrexate: a phase 3, randomised studyHiroaki Matsuno, Ernest Choy, Paul Emery, et al.
Arthritis and Rheumatism|September 12, 2013
Indocyanine green-enhanced fluorescence optical imaging in patients with early and very early arthritis: a comparative study with magnetic resonance imagingStephanie G Werner, Hans-Eckhard Langer, Peter Schott, et al.
European Journal of Immunology|November 13, 2019
Selective depletion of plasma cells in vivo based on the specificity of their secreted antibodiesQingyu Cheng, Andreas Pelz, Adriano Taddeo, et al.
Arthritis Research & Therapy|June 12, 2020
Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studiesMark C Genovese, Roy Fleischmann, Alan Kivitz, et al.
RMD Open|January 27, 2017
SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndromeThomas Rose, Franziska Szelinski, Anna Lisney, et al.
Annals of the Rheumatic Diseases|September 8, 2012
The US7 score is sensitive to change in a large cohort of patients with rheumatoid arthritis over 12 months of therapyTina M Backhaus, Sarah Ohrndorf, Herbert Kellner, et al.
Annals of the Rheumatic Diseases|March 19, 2011
Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trialVibeke Strand, Josef S Smolen, Ronald F van Vollenhoven, et al.
Pageof 34

Showing results (151-160 of 335) with videos related to

Sort By:
Pageof 34
RMD Open|May 28, 2021
Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposureGerd R Burmester, Peter Nash, Bruce E Sands, et al.
Rheumatology and Therapy|April 29, 2024
Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical TrialsGerd R Burmester, Jayne Stigler, Andrea Rubbert-Roth, et al.
Advances in Therapy|January 3, 2024
Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled TrialsEduardo Mysler, Gerd R Burmester, Christopher D Saffore, et al.
EULAR Rheumatology Open|June 29, 2026
Efficacy, safety, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab intravenously administered to adults with active rheumatoid arthritis and an inadequate response to methotrexate: a phase 3, randomised studyHiroaki Matsuno, Ernest Choy, Paul Emery, et al.
Arthritis and Rheumatism|September 12, 2013
Indocyanine green-enhanced fluorescence optical imaging in patients with early and very early arthritis: a comparative study with magnetic resonance imagingStephanie G Werner, Hans-Eckhard Langer, Peter Schott, et al.
European Journal of Immunology|November 13, 2019
Selective depletion of plasma cells in vivo based on the specificity of their secreted antibodiesQingyu Cheng, Andreas Pelz, Adriano Taddeo, et al.
Arthritis Research & Therapy|June 12, 2020
Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studiesMark C Genovese, Roy Fleischmann, Alan Kivitz, et al.
RMD Open|January 27, 2017
SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndromeThomas Rose, Franziska Szelinski, Anna Lisney, et al.
Annals of the Rheumatic Diseases|September 8, 2012
The US7 score is sensitive to change in a large cohort of patients with rheumatoid arthritis over 12 months of therapyTina M Backhaus, Sarah Ohrndorf, Herbert Kellner, et al.
Annals of the Rheumatic Diseases|March 19, 2011
Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trialVibeke Strand, Josef S Smolen, Ronald F van Vollenhoven, et al.
Pageof 34